China Strives To E-Monitor All Marketed Drugs Before FY16
This article was originally published in PharmAsia News
Executive Summary
China FDA will continue to enhance drug safety through e-monitoring and penalties despite a number of existing hurdles, said Deputy Commissioner Yin Li.